Target intelligence / Profile preview

Sorbin and SH3 domain-containing protein 2 (SORBS2)

Target
SORBS2
Molecular classification
Adaptor protein, Structural constituent of cytoskeleton, RNA-binding protein, Cytoskeletal anchor, Other (not an enzyme, receptor, ion channel, transporter, or transcription factor)
01

Overview

Sorbin and SH3 domain-containing protein 2 (SORBS2) is an adaptor and RNA-binding protein characterized by an N-terminal sorbin homology (SoHo) domain and three C-terminal SH3 domains. SORBS2 is highly enriched in cardiac and skeletal muscle—localizing at intercalated discs in heart tissue, Z-bands in cardiomyocytes, and at actin stress fibers, focal adhesions, and cell junctions in other cell types. Its physiological functions include connecting integrins to the actin cytoskeleton, regulating cell adhesion, cytoskeletal organization, and signal transduction by assembling complexes involving the Abelson family of non-receptor tyrosine kinases (Arg/Abl), alpha-actinin, vinculin, flotillin, and other partners. SORBS2 expression is tightly regulated; dysregulation is associated with cardiac pathologies such as hypertrophy and fibrosis, electrical remodeling, and congenital heart defects, and also with muscular dystrophies and cancer cell migration. SORBS2 is not a classical receptor, enzyme, transporter, or ion channel, but rather a scaffolding protein involved in structural and signaling roles within the cell.

Other names
ArgBP2ARGBP2KIAA0777PRO0618sorbin and SH3 domain containing 2Arg-binding protein 2SorbinArg/Abl-interacting protein 2Arg/Abl interacting protein
02

Biological functions

Cell adhesionCytoskeletal organizationIntegrin interaction, focal adhesion assemblySignal transduction (via interactions with Arg/Abl kinases)Regulation of actin stress fibers and myofibril assemblyMaintenance of electrical integrity in cardiac muscleRegulation of apoptosis (through signaling complexes)Regulation of cardiac fibrosis
03

Disease associations

Cardiovascular disease (notably heart failure, cardiac fibrosis, hypertrophy, arrhythmogenic cardiomyopathy, congenital heart defects)Cancer (involvement in cell migration and epithelial cell junction dynamics; altered expression linked to tumor cell migration)Muscular dystrophy (associated with facioscapulohumeral muscular dystrophy)
04

Safety considerations

no notable direct safety concerns or therapeutic challenges reported in sources; functional loss or overexpression may lead to pathological remodeling in the heart
05

Biomarkers

Increased SORBS2 expression as biomarker for heart failure severityPotential marker in muscular dystrophy (expression alteration)

Beyond the preview

Go deeper on Sorbin and SH3 domain-containing protein 2 (SORBS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sorbin and SH3 domain-containing protein 2 (SORBS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call